Blog Immunotherapy 360:

Image

The Immunotherapy 360 blog space features articles that encompass prominent issues related to immunotherapy. These are written with the assistance of the staff at AIM at Melanoma, AIM with Immunotherapy and health care practitioners.

If you have an idea for a future article, please reach out to us on our contact page!

Featured image for “Regeneron Announces Approval of Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous-Cell Carcinoma with a High Risk of Recurrence After Surgery and Radiation  ”

Regeneron Announces Approval of Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous-Cell Carcinoma with a High Risk of Recurrence After Surgery and Radiation  

October 9, 2025
The first and only FDA-approved immunotherapyfor this patient population October 8, 2025 (Sacramento, California) The FDA has approved the PD-1…
Featured image for “Subcutaneous Versus Intravenous Nivolumab Formulations: Important Considerations for Patient Care”

Subcutaneous Versus Intravenous Nivolumab Formulations: Important Considerations for Patient Care

September 23, 2025
In December 2024, the FDA approved a subcutaneous formulation of the immune checkpoint inhibitor nivolumab across adult, solid tumor nivolumab…
Featured image for “Anti-TIGIT Immunotherapy in Melanoma”

Anti-TIGIT Immunotherapy in Melanoma

September 1, 2025
Checkpoint Inhibitor Therapies and Unmet Needs Checkpoint inhibitor therapies have been a major advance for patients with melanoma. Recent long-term…
Featured image for “A Strategy Aimed at Reducing the Toxicity Associated with TIL Therapy”

A Strategy Aimed at Reducing the Toxicity Associated with TIL Therapy

August 24, 2025
Introduction Tumor-infiltrating lymphocyte (TIL) therapy, such as lifileucel, is approved for use in adults with unresectable, advanced melanoma that has…
Featured image for “Observations Learned from Steroid Use to Manage Immune-Related Adverse Events (irAEs)”

Observations Learned from Steroid Use to Manage Immune-Related Adverse Events (irAEs)

August 6, 2025
Helping an individual’s immune system to re-recognize and identify cancer cells has proven to be the most effective drug strategy…
Featured image for “Experiencing the Worst Effects Indicates the Best News for Patients”

Experiencing the Worst Effects Indicates the Best News for Patients

June 4, 2025
The silver lining for patients experiencing side effects related to immunotherapy and targeted therapy for cancer treatment is that these…
Featured image for “What’s the Issue of Concurrent Statins During Immune Checkpoint Inhibitor Therapy?”

What’s the Issue of Concurrent Statins During Immune Checkpoint Inhibitor Therapy?

May 28, 2025
Introduction Recently, published studies have sparked discussion about combining statins with immune checkpoint inhibitors during cancer treatment. The Journal of…
Featured image for “Ocular Toxicities Associated with Vedotins and Other Antibody-Drug Conjugates are Manageable”

Ocular Toxicities Associated with Vedotins and Other Antibody-Drug Conjugates are Manageable

April 23, 2025
Introduction In recent years, several antibody-drug conjugates have received approval for the treatment of gynecological cancers, adding powerful tools to…
Featured image for “Potential Biomarker May Indicate T-VEC Efficacy”

Potential Biomarker May Indicate T-VEC Efficacy

March 18, 2025
A new study from Harvard University and the Massachusetts General Hospital may have uncovered a biomarker indicating a strong response…
Featured image for “Colitis – A Common but Serious Adverse Event”

Colitis – A Common but Serious Adverse Event

December 10, 2024
Immune-related adverse events (irAEs) are unintended consequences of immunotherapies used in cancer treatment. Side effects can range from mild to…

Recent Posts

Featured image for “Regeneron Announces Approval of Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous-Cell Carcinoma with a High Risk of Recurrence After Surgery and Radiation  ”
Oct. 09, 2025

Regeneron Announces Approval of Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous-Cell Carcinoma with a High Risk of Recurrence After Surgery and Radiation  

Featured image for “Subcutaneous Versus Intravenous Nivolumab Formulations: Important Considerations for Patient Care”
Sep. 23, 2025

Subcutaneous Versus Intravenous Nivolumab Formulations: Important Considerations for Patient Care

Featured image for “Anti-TIGIT Immunotherapy in Melanoma”
Sep. 01, 2025

Anti-TIGIT Immunotherapy in Melanoma

Post Categories